Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2016 Nov 30;9:133. doi: 10.1186/s13045-016-0364-0

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

George S Laszlo 1, Todd A Alonzo 2,3, Chelsea J Gudgeon 1, Kimberly H Harrington 1, Alex Kentsis 4,5,6, Robert B Gerbing 3, Yi-Cheng Wang 3, Rhonda E Ries 1, Susana C Raimondi 3,7, Betsy A Hirsch 3,8, Alan S Gamis 3,9, Soheil Meshinchi 1,3,10, Roland B Walter 1,11,12,
PMCID: PMC5129595  PMID: 27903291

Erratum

The original article [1] contains an omission of information in the Financial support sub-section of the Declarations section.

The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of co-author Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.

Footnotes

The online version of the original article can be found under doi:10.1186/s13045-015-0215-4.

Reference

  • 1.Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. J Hematol Oncol. 2015;8:115. doi: 10.1186/s13045-015-0215-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES